Interphase FISH Does Not Improve the Detection of DEL(5q) and DEL(20q) in Myelodysplastic Syndromes

被引：0
|
作者：
Douet-Guilbert, Nathalie [1 ,2 ,3 ]
Herry, Angele [1 ]
Le Bris, Marie-Josee [2 ]
Gueganic, Nadia [1 ]
Bovo, Clement [1 ]
Morel, Frederic [1 ,2 ,3 ]
De Braekeleer, Marc [1 ,2 ,3 ]
机构：
[1] Univ Bretagne Occidentale, Lab Histol Embryol & Cytogenet, Fac Med & Sci Sante, F-29238 Brest 3, France
[2] CHU Brest, Hop Morvan, Serv Cytogenet Cytol & Biol Reprod, F-29285 Brest, France
[3] INSERM, U613, Brest, France
来源：
ANTICANCER RESEARCH | 2011年 / 31卷 / 03期
关键词：
Interphase FISH; MDS; normal karyotype; del(5q); del(20q); IN-SITU HYBRIDIZATION; SCORING SYSTEM; MYELOPROLIFERATIVE DISORDERS; CONVENTIONAL CYTOGENETICS; MOLECULAR CYTOGENETICS; CLASSIFICATION; DIAGNOSIS; DELETION; ABERRATIONS; TRISOMY-8;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cytogenetic abnormalities identified by conventional cytogenetics (CC) have important prognostic and therapeutic roles in myelodysplastic syndromes (MDS). Fluorescence in situ hybridization (FISH) complements CC since it is able to evaluate large numbers of interphase and metaphase nuclei. The question has been raised as to whether interphase FISH in addition to CC is able to imprive the level of detection of del(5q) and del(20q) in MDS. This study performed interphase FISH with 5q and 20q probes in a series of 158 MDS patients with a normal karyotype. No hidden del(5q) or del(20q) was detected. A review of the literature identified 20 patients (1.96%) of 1018 patients (including the current series) and 3 (0.91%) of 331 patients to have a del(5q) or del(20q). Therefore, interphase FISH adds little, if any, improvement to the probability of detecting these deletions. However, interphase FISH is recommended in patients with no cell growth or when fewer than 20 metaphases are available for CC analysis.
引用
收藏
页码：1007 / 1010
页数：4
相关论文
共 50 条
  • [41] Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
    Drusbosky, Leylah M.
    Cogle, Christopher R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [42] Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment
    Acha, Pamela
    Mallo, Mar
    Sole, Francesc
    CANCERS, 2022, 14 (22)
  • [43] A NOVEL PCR-BASED ASSAY FOR TARGETED QUANTIFICATION OF DEL(5Q) IN MYELODYSPLASTIC SYNDROMES
    Jann, J. C.
    Nowak, D.
    Nolte, F.
    Fey, S.
    Nowak, V.
    Oblaender, J.
    Pressler, J.
    Fabarius, A.
    Haferlach, C.
    Medyouf, H.
    Hofmann, W. K.
    Mossner, M.
    LEUKEMIA RESEARCH, 2015, 39 : S80 - S80
  • [44] Treatment of myelodysplastic syndromes with del 5q before the lenalidomide era:: The GFM experience.
    Kelaidi, Charikleia
    Park, Sophie
    Brechignac, Sabine
    Mannone, Lionel
    Vey, Norbert
    Dombret, Herve
    Aljassem, Lina
    Starnatoullas, Aspasia
    Ades, Lionel
    Giraudier, Setphane
    de Botton, Stephane
    Mahe, Beatrice
    Lepelley, Pascale
    Picard, Fracoise
    Leroux, Genevieve
    Daniel, Marie-Threrese
    Bouscary, Didier
    Dreyfus, Francois
    Fenaux, Pierre
    BLOOD, 2006, 108 (11) : 757A - 757A
  • [45] A Calcium-Dependent Pathway Determines Response to Lenalidomide in Del(5q) Myelodysplastic Syndromes
    Fang, Jing
    Liu, Xiaona
    Bolanos, Lyndsey
    Barker, Brenden
    Rigolino, Carmela
    Cortelezzi, Agostino
    Oliva, Esther Natalie
    MacBeth, Kyle J.
    Komurov, Kakajan
    Starczynowski, Daniel T.
    BLOOD, 2014, 124 (21)
  • [46] Deletion of 5q31 is observed in megakaryocytic cells in patients with myelodysplastic syndromes and a del(5q), including the 5q-syndrome
    Godon, C
    Talmant, P
    Garand, R
    Accart, F
    Bataille, R
    Avet-Loiseau, H
    GENES CHROMOSOMES & CANCER, 2000, 29 (04): : 350 - 352
  • [47] Fluorescence In Situ Hybridization (FISH) Testing for-5/5q,-7/7q,+8, and del(20q) in Primary Myelodysplastic Syndrome (MDS) Is Unnecessary in the Setting of an Adequate Conventional Cytogenetic Study
    Pitchford, Clovis W.
    Hettinga, Ana C.
    Reichard, Kaaren K.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 132 (04) : 623 - 623
  • [48] Inflammation in del(20q): a MST opportunity?
    Lane, Steven W.
    BLOOD, 2019, 134 (20) : 1685 - 1686
  • [49] SURVIVAL OF PATIENTS WITH DE NOVO MYELODYSPLASTIC SYNDROME AND del(5q)
    Gritsaev, S. V.
    Martynkevich, I. S.
    Petrova, E. V.
    Martynenko, L. S.
    Kostroma, I. I.
    Ivanova, M. P.
    Tsybakova, N. Yu.
    Kozlovskaya, M. A.
    Sergeyev, A. N.
    Tiranova, S. A.
    Potikhonova, N. A.
    Abdulkadyrov, K. M.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2013, 58 (01): : 3 - 9
  • [50] The detection of bone marrow hematogones by multiparameteric flow cytometric analysis in myelodysplastic syndromes predicts the presence of del 5q
    Jones, Arthur G.
    Li, Y.
    Gray, Brian A.
    Zori, Roberto T.
    Braylan, Raul C.
    Al-Quran, Samer Z.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 130 (04) : 652 - 652
12345